KR920005984A - 푸란 유도체를 함유하는 제약 조성물 - Google Patents

푸란 유도체를 함유하는 제약 조성물 Download PDF

Info

Publication number
KR920005984A
KR920005984A KR1019910015760A KR910015760A KR920005984A KR 920005984 A KR920005984 A KR 920005984A KR 1019910015760 A KR1019910015760 A KR 1019910015760A KR 910015760 A KR910015760 A KR 910015760A KR 920005984 A KR920005984 A KR 920005984A
Authority
KR
South Korea
Prior art keywords
methyl
composition
ranitidine
salt
alkaline salt
Prior art date
Application number
KR1019910015760A
Other languages
English (en)
Other versions
KR100196308B1 (ko
Inventor
리챠드 스미스 노만
로이 헵펜스탈 콜린
죤 더글라스 스테판
Original Assignee
원본미기재
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 글락소 그룹 리미티드 filed Critical 원본미기재
Publication of KR920005984A publication Critical patent/KR920005984A/ko
Application granted granted Critical
Publication of KR100196308B1 publication Critical patent/KR100196308B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

푸란 유도체를 함유하는 제약 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 주석산 및 시트르산 중 선택되는 카르복실산과 비스무스와의 착물과 라니티딘 사이에 형성된 염 및 알칼리성 염으로 이루어진 경구 투여용 고체 단위 투여 형태의 제약 조성물.
  2. 제1항에 있어서, 투여 단위당 200 내지 800mg의 라니티딘 비스무스 카르복실레이트를 함유하는 조성물.
  3. 제1 또는 2항에 있어서, 알칼리성 염 2 내지 20% w/w을 함유하는 조성물.
  4. 제1 또는 2항에 있어서, 알칼리성 염 2 내지 8% w/w을 함유하는 조성물.
  5. 제1 내지 4항중 어느 한 항에 있어서, 라니티딘 비스무스 카르복실레이트 50 내지 95% w/w을 함유하는 조성물.
  6. 제1 내지 5항중 어느 한 항에 있어서, 라니티딘의 염이 N-[2-[[[5-[(디메틸아미노)메틸]-2-푸라닐]메틸]티오]에틸]-N'-메틸-2-니트로-1,1-에텐디아민 2-히드록시-1,2,3-프로판트리카르복실레이트비스무스(3+)착물 또는 N-[2-[[[5-[(디메티아미노)메틸]-2-푸라닐]메틸]티오]에틸]-N'-메틸-2-니트로-1,1-에텐디아민 [R-(R*R*)]-2,3-디히드록시부탄디오에이트비스무스(3+)착물인 조성물.
  7. 제1 내지 6항중 어느 한 항에 있어서, 알칼리성 염이 탄산염, 중탄산염, 시트르산염, 인산염, 아세트산염 또는 염산염인 조성물.
  8. 제1 내지 6항중 어느 한 항에 있어서, 알칼리성 염이 알칼리금속 또는 알칼리 토금속 탄산염 또는 중탄산염 또는 이들의 혼합물인 조성물.
  9. 제1 내지 6항중 어느 한 항에 있어서, 알칼리성염이 탄산나트륨 및(또는) 중탄산 나트륨인 조성물.
  10. 제1 내지 5항중 어느 한 항에 있어서, 라니티딘 비스무스카르복실레이트가 N-[2-[[[5-[(디메틸아미노)메틸]-2-푸라닐]메틸]티오]에틸]-N'-메틸-2-니트로-1,1-에텐디아민 2-히드록시-1,2,3-프로판트리카르복실레이트비스무스(3+)착물이고, 알칼리성 염이 탄산 나트륨인 조성물.
  11. 제1 내지 10항중 어느 한 항에 있어서, 정제 형태인 조성물.
  12. 제1 내지 11항중 어느 한 항에 있어서, 일종 이상의 생리학상 허용가능한 담체 또는 부형제도 함유하는 조성물.
  13. 라니티딘 비스무스 카르복실레이트 및 알칼리성 염을 경구투여에 적합한 고체 투여 형태로 가공시키는 것으로 이루어진 제1 내지 12항중 어느 한 항 기재의 제약 조성물의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910015760A 1990-09-11 1991-09-10 푸란 유도체를 함유하는 제약 조성물 KR100196308B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9019875.5 1990-09-11
GB909019875A GB9019875D0 (en) 1990-09-11 1990-09-11 Pharmaceutical compositions
NO920408A NO179694C (no) 1990-09-11 1992-01-30 Farmasöytiske preparater inneholdende ranitidinderivater
PCT/EP1992/000498 WO1993017679A1 (en) 1990-09-11 1992-03-05 Compositions containing ranitidine/bismuth carboxylates salts

Publications (2)

Publication Number Publication Date
KR920005984A true KR920005984A (ko) 1992-04-27
KR100196308B1 KR100196308B1 (ko) 1999-06-15

Family

ID=47884627

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910015760A KR100196308B1 (ko) 1990-09-11 1991-09-10 푸란 유도체를 함유하는 제약 조성물

Country Status (33)

Country Link
US (1) US5456925A (ko)
EP (1) EP0558779B1 (ko)
JP (1) JPH0692849A (ko)
KR (1) KR100196308B1 (ko)
AT (2) AT405134B (ko)
AU (2) AU640816B2 (ko)
BE (1) BE1005115A5 (ko)
BG (1) BG61931B1 (ko)
CA (1) CA2050970C (ko)
CH (1) CH683068A5 (ko)
CY (1) CY1988A (ko)
DE (2) DE4130061A1 (ko)
DK (1) DK159191A (ko)
ES (1) ES2072647T3 (ko)
FI (1) FI944047A (ko)
FR (1) FR2666508B1 (ko)
GB (2) GB9019875D0 (ko)
HK (1) HK60894A (ko)
HU (1) HU211846A9 (ko)
IE (1) IE65049B1 (ko)
IL (1) IL99428A (ko)
IT (1) IT1249696B (ko)
MX (1) MX9101009A (ko)
NL (1) NL194907C (ko)
NO (1) NO179694C (ko)
NZ (1) NZ239731A (ko)
OA (1) OA10093A (ko)
RO (1) RO112084B1 (ko)
RU (1) RU2108097C1 (ko)
SE (1) SE509694C2 (ko)
SK (1) SK279591B6 (ko)
WO (1) WO1993017679A1 (ko)
ZA (1) ZA917176B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
DE69228738D1 (de) * 1991-12-06 1999-04-29 Glaxo Group Ltd Zusammensetzungen zur Behandlung von entzündlichen Zuständen oder Analgesie, die Ranitidin Wismuth Citrat und einen NSAID enthalten
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
GB9501560D0 (en) 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
US6117412A (en) * 1995-01-26 2000-09-12 Nycomed Imaging As Non-cluster type bismuth compounds
WO2000010562A1 (fr) * 1998-08-18 2000-03-02 Leonidov Nikolai B Forme physiquement stable et amorphe aux rayons x de ranitidine d'hydrochlorure ayant une action anti-ulcere accrue, et procede de production
EP1104673A1 (en) * 1999-11-30 2001-06-06 Bayer Classics A hydrogen carbonate-containing, desintegrating agent-free pharmaceutical composition
KR100412290B1 (ko) * 2001-11-27 2003-12-31 주식회사 동구제약 라니티딘 함유 현탁제 조성물 및 그의 제조방법
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
US9629809B2 (en) 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
WO2010011522A1 (en) * 2008-07-21 2010-01-28 Albemarle Corporation High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
CN115697354A (zh) * 2020-06-01 2023-02-03 香港大学 用于治疗sars-cov-2感染的组合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608257A (en) * 1984-01-03 1986-08-26 Board Of Regents For Oklahoma State University Composition and method for treating heat stress
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
EP0282132B1 (en) * 1987-03-09 1992-09-30 The Procter & Gamble Company Compositions and their use for treating gastrointestinal disorders
DE3710462A1 (de) * 1987-03-30 1988-10-13 Heumann Pharma Gmbh & Co Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
CH679582A5 (ko) * 1988-07-18 1992-03-13 Glaxo Group Ltd
ES2040307T3 (es) * 1988-10-08 1993-10-16 Dr. R. Pfleger Chemische Fabrik Gmbh Procedimiento para producir un preparado medicamentoso liquido que contiene bismuto.
AU641903B2 (en) * 1988-10-26 1993-10-07 Glaxo Group Limited Carboxylic acid derivatives
US5013560A (en) * 1989-03-17 1991-05-07 The Procter & Gamble Company Microbially-stable bismuth-containing liquid pharmaceutical suspensions
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
CY1988A (en) 1997-09-05
WO1993017679A1 (en) 1993-09-16
US5456925A (en) 1995-10-10
GB9119284D0 (en) 1991-10-23
NL194907C (nl) 2003-07-04
NO920408L (no) 1993-08-02
ITRM910673A0 (it) 1991-09-10
EP0558779A1 (en) 1993-09-08
RU2108097C1 (ru) 1998-04-10
NO179694B (no) 1996-08-26
SE509694C2 (sv) 1999-02-22
SK279591B6 (sk) 1999-01-11
AT405134B (de) 1999-05-25
AU640816B2 (en) 1993-09-02
FI944047A0 (fi) 1994-09-02
NO920408D0 (no) 1992-01-30
RO112084B1 (ro) 1997-05-30
IT1249696B (it) 1995-03-09
CA2050970A1 (en) 1992-03-12
FI944047A (fi) 1994-09-02
ES2072647T3 (es) 1995-07-16
DK159191D0 (da) 1991-09-10
ATA180191A (de) 1998-10-15
DK159191A (da) 1992-03-12
HU211846A9 (en) 1995-12-28
KR100196308B1 (ko) 1999-06-15
NL9101533A (nl) 1992-04-01
SK106094A3 (en) 1995-02-08
ATE122883T1 (de) 1995-06-15
BG99021A (bg) 1995-06-30
GB2248185B (en) 1994-02-02
BG61931B1 (bg) 1998-10-30
OA10093A (en) 1996-12-18
NL194907B (nl) 2003-03-03
SE9102604L (sv) 1992-03-12
GB9019875D0 (en) 1990-10-24
DE4130061A1 (de) 1992-03-12
NO179694C (no) 1996-12-04
JPH0692849A (ja) 1994-04-05
NZ239731A (en) 1993-10-26
ZA917176B (en) 1992-06-24
GB2248185A (en) 1992-04-01
AU8375791A (en) 1992-03-19
CA2050970C (en) 2002-11-19
EP0558779B1 (en) 1995-05-24
BE1005115A5 (fr) 1993-04-27
FR2666508A1 (fr) 1992-03-13
IE913191A1 (en) 1992-04-22
IL99428A (en) 1996-06-18
HK60894A (en) 1994-07-08
SE9102604D0 (sv) 1991-09-10
FR2666508B1 (fr) 1994-02-18
DE69202696D1 (de) 1995-06-29
IE65049B1 (en) 1995-10-04
AU1334792A (en) 1993-10-05
CH683068A5 (fr) 1994-01-14
ITRM910673A1 (it) 1993-03-10
IL99428A0 (en) 1992-08-18
MX9101009A (es) 1992-05-04

Similar Documents

Publication Publication Date Title
KR920005984A (ko) 푸란 유도체를 함유하는 제약 조성물
KR910002826A (ko) 푸란 유도체
JPS5513275A (en) Prodrug of non-steroid anti-inflammatory drug having improved absorption and anti-inflammatory drug composition comprising it
GB1413648A (en) Hypolipedemic acitve alkoxy and alkylthio-furoic acids and esters
RU94040869A (ru) Фармацевтические композиции, содержащие соли ранитидина и карбоксилаты висмута, и способ их получения
JPS56152419A (en) Drug active to cardiad vessel, containing 1,2,5-oxydiazole-2-oxide substituted as pharmaceutical substance
HUT38097A (en) Process for preparing substituted benzopyrans and pharmaceutical compositions containing them as active substances
ES476106A1 (es) Procedimiento para la preparacion de 4-espectinomicilamina.
KR910021394A (ko) 카르복실산 유도체
KR910014124A (ko) 콜로이달 비스무트 서브시트레이트(cbs)를 함유하는 삼킬수 있는 투여 단위
IL83086A0 (en) Stable,injectable solutions of vinca dimer salts
ES427079A1 (es) Un metodo de preparacion de fenotiazidas sustituidas por fluor en la posicion 7.
KR890006235A (ko) 피페리디노알칸올용 제약 조성물
UA27002C2 (uk) Фармацевтичhа композиція в твердій одиhичhій дозоваhій формі, придатhій для оральhого застосуваhhя при розладах шлуhково-кишкового тракту, яка містить сіль раhітидиhу і карбоксилату вісмуту та спосіб її одержаhhя
JP2007077116A (ja) 臓器線維化抑制剤
JPS57158719A (en) Rectal administration pharmaceutical
KR890011594A (ko) 4-아로일이미다졸-2-온의 제약 조성물
WO1995010274A1 (en) Aqueous pharmaceutical composition
KR930001906A (ko) 벤즈이미다졸린-2-옥소-1-카복실산 유도체의 용도
GB1174988A (en) Novel Benzylaminoimidazoline Derivatives, the preparation thereof and Compositions containing the same
IL64839A (en) N-arylmethyl-4-(methylanilino)-5-sulfamoyl-anthranilic acids,a process for their preparation and pharmaceutical compositions containing them
GB1464082A (en) Pharmaceutical 'ompositions containing benzylamines
ES369646A1 (es) Un procedimiento de preparacion de los derivados de acido 5-tiazol carboxilico.
JPS5675427A (en) Antiarteriosclerotic agent containing procainamide hydrochloride
SI8911427B (sl) Postopek za pripravo soli ranitidina z bizmutoviml kompleksi karboksilnih kislin

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060106

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee